Last Price$437.20.0%
Market Cap$36.1B
P/EBIT LTM
30.5x
5Y avg
46.1x
Medical - Diagnostics & Research industry
median
(0.6x)
Stock quality & Intrinsic value
7/10
(0.5%) overvalued
IDEXX Laboratories, Inc. P/EBIT LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBIT LTM | 21.3x | 21.1x | 19.2x | 27.6x | 12.2x | 18.9x | 20.5x | 18.3x | 19.7x | 20.6x | 24.9x | 25.1x | 31.4x | 34.3x | 33.9x | 40.6x | 68.0x | 61.1x | 38.8x | 42.8x |
Overvalued or undervalued?
Check the intrinsic value for IDXX
and see if it's the right time to invest.
IDEXX Laboratories, Inc. (IDXX) P/EBIT LTM comparison analysis
General
LTM P/EBIT LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
IDEXX Laboratories, Inc.IDXX
32.0x
8.7%
25.2%
23.1%
Median Peer Set
22.6x
(0.5%)
(6.5%)
14.0%
Danaher CorporationDHR
31.1x
(0.1%)
(17.9%)
16.3%
Thermo Fisher Scientific Inc.TMO
27.4x
(4.6%)
(12.4%)
14.0%
Waters CorporationWAT
26.4x
(0.5%)
(7.9%)
21.7%
Agilent Technologies, Inc.A
24.6x
(4.7%)
5.0%
19.8%
Mettler-Toledo International Inc.MTD
22.6x
2.2%
12.7%
22.3%
IQVIA Holdings Inc.IQV
15.0x
2.8%
2.4%
8.9%
Quest Diagnostics IncorporatedDGX
14.2x
(6.4%)
(6.5%)
9.2%
Illumina, Inc.ILMN
10.3x
(2.9%)
4.6%
(28.0%)
Natera, Inc.NTRA
(76.4x)
32.0%
(32.1%)
(40.2%)
IDXX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 549.2 0.0% | 638.1 16.2% | 739.1 15.8% | 922.6 24.8% | 1,024.0 11.0% | 1,031.6 0.7% | 1,103.4 7.0% | 1,218.7 10.4% | 1,293.3 6.1% | 1,377.1 6.5% | 1,485.8 7.9% | 1,601.9 7.8% | 1,775.4 10.8% | 1,969.1 10.9% | 2,213.2 12.4% | 2,406.9 8.8% | 2,706.7 12.5% | 3,215.4 18.8% | 3,367.3 4.7% | 3,661.0 8.7% |
| Cost of Goods Sold (COGS) | 270.2 | 315.2 | 359.6 | 459.0 | 494.3 | 505.4 | 524.8 | 572.2 | 594.2 | 620.9 | 669.7 | 711.6 | 800.0 | 871.7 | 971.7 | 1,041.4 | 1,135.6 | 1,325.9 | 1,363.0 | 1,471.0 |
% margin | 279.0 50.8% | 322.9 50.6% | 379.5 51.3% | 463.5 50.2% | 529.8 51.7% | 526.3 51.0% | 578.6 52.4% | 646.5 53.0% | 699.1 54.1% | 756.1 54.9% | 816.1 54.9% | 890.3 55.6% | 975.4 54.9% | 1,097.4 55.7% | 1,241.5 56.1% | 1,365.5 56.7% | 1,571.0 58.0% | 1,889.4 58.8% | 2,004.3 59.5% | 2,190.0 59.8% |
| Operating Expenses | 171.0 | 207.6 | 251.6 | 327.3 | 357.3 | 350.3 | 374.7 | 410.3 | 436.6 | 489.4 | 555.9 | 582.1 | 625.2 | 684.4 | 750.2 | 812.7 | 876.5 | 957.4 | 1,105.6 | 1,092.8 |
| Research & Development Expenses (R&D) | 35.4 | 40.9 | 53.6 | 67.3 | 70.6 | 65.1 | 68.6 | 76.0 | 82.0 | 88.0 | 98.3 | 99.7 | 101.1 | 109.2 | 117.9 | 133.2 | 141.2 | 161.0 | 254.8 | 191.0 |
| Selling, General & Administrative Expenses (SG&A) | 135.6 | 166.6 | 198.0 | 260.0 | 285.3 | 285.2 | 306.1 | 334.2 | 354.6 | 401.4 | 457.6 | 482.5 | 524.1 | 575.2 | 632.3 | 679.5 | 735.3 | 796.4 | 850.8 | 901.9 |
% margin | 108.0 19.7% | 115.3 18.1% | 127.9 17.3% | 136.2 14.8% | 172.5 16.8% | 176.0 17.1% | 203.9 18.5% | 236.2 19.4% | 262.6 20.3% | 266.8 19.4% | 260.3 17.5% | 299.9 18.7% | 350.2 19.7% | 413.0 21.0% | 491.3 22.2% | 552.8 23.0% | 694.5 25.7% | 932.0 29.0% | 898.8 26.7% | 1,097.1 30.0% |
| Interest Income | 3.1 | 3.1 | 0.0 | 0.0 | 2.3 | 0.5 | 0.7 | 1.7 | 1.9 | 1.9 | 1.7 | 2.5 | 3.7 | 5.3 | 1.2 | 0.4 | 0.6 | 0.4 | 1.1 | 5.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 4.6 | 1.4 | 1.8 | 1.8 | 1.9 | 3.5 | 13.7 | 26.8 | 28.4 | 32.0 | 33.6 | 30.6 | 32.5 | 29.4 | 38.8 | 41.6 |
| Pre-tax Income | 111.1 | 118.5 | 130.8 | 134.8 | 170.2 | 174.5 | 202.1 | 234.4 | 260.6 | 263.3 | 246.6 | 273.1 | 321.8 | 381.1 | 457.7 | 522.2 | 662.0 | 902.7 | 860.0 | 1,061.2 |
% effective tax rate | 33.2 29.9% | 40.7 34.3% | 37.2 28.5% | 40.8 30.3% | 54.0 31.7% | 52.3 30.0% | 60.8 30.1% | 72.7 31.0% | 82.3 31.6% | 75.5 28.7% | 64.6 26.2% | 81.0 29.7% | 99.8 31.0% | 117.8 30.9% | 80.7 17.6% | 94.4 18.1% | 79.9 12.1% | 157.8 17.5% | 180.9 21.0% | 216.1 20.4% |
% margin | 78.3 14.3% | 78.3 12.3% | 93.7 12.7% | 94.0 10.2% | 116.2 11.3% | 122.2 11.8% | 141.3 12.8% | 161.8 13.3% | 178.3 13.8% | 187.8 13.6% | 181.9 12.2% | 192.1 12.0% | 222.0 12.5% | 263.1 13.4% | 377.0 17.0% | 427.7 17.8% | 581.8 21.5% | 744.8 23.2% | 679.1 20.2% | 845.0 23.1% |
| EPS | 0.57 | 0.60 | 0.75 | 0.77 | 0.97 | 1.04 | 1.23 | 1.43 | 1.62 | 1.77 | 1.82 | 2.07 | 2.47 | 3.00 | 4.34 | 4.97 | 6.82 | 8.74 | 8.12 | 10.17 |
| Diluted EPS | 0.55 | 0.57 | 0.71 | 0.73 | 0.94 | 1.00 | 1.19 | 1.39 | 1.59 | 1.74 | 1.79 | 2.05 | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | 8.60 | 8.03 | 10.06 |
% margin | 126.5 23.0% | 139.7 21.9% | 157.7 21.3% | 177.3 19.2% | 223.6 21.8% | 226.2 21.9% | 250.5 22.7% | 284.7 23.4% | 316.2 24.4% | 322.3 23.4% | 319.8 21.5% | 370.3 23.1% | 431.7 24.3% | 501.4 25.5% | 575.7 26.0% | 643.7 26.7% | 793.8 29.3% | 1,039.9 32.3% | 1,014.5 30.1% | 1,217.7 33.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is IDEXX Laboratories, Inc.'s P/EBIT LTM?
As of today, Microsoft Corp's last 12-month P/EBIT LTM is 30.5x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBIT LTM for IDEXX Laboratories, Inc. have been 43.9x over the past three years, and 48.4x over the past five years.
2) Is IDEXX Laboratories, Inc.'s P/EBIT LTM Good?
As of today, IDEXX Laboratories, Inc.'s P/EBIT LTM is 30.5x, which is higher than industry median of (0.6x). It indicates that IDEXX Laboratories, Inc.'s P/EBIT LTM is Bad.